Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status approved; investigational
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 62350-0077; 68682-272; 72189-084; 0168-0432; 22365-121; 51672-4174; 99207-271; 66039-829; 71052-160; 64552-4008; 45802-368; 51552-1538; 62147-0087; 51672-4145; 63629-8818; 68462-536; 51927-0168; 72643-006; 0093-3133; 99207-260; 99207-270; 99207-276; 58175-0397; 62147-0072
UNII P1QW714R7M
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.038--Not Available
Application site cellulitis11.02.01.028; 08.02.01.043; 23.11.02.001; 12.07.01.043--Not Available
Application site erosion23.07.03.011; 12.07.01.021; 08.02.01.0210.003029%Not Available
Application site scab23.03.03.050; 12.07.01.042; 08.02.01.0420.001624%Not Available
Treatment failure08.06.01.0170.002371%Not Available
Oral herpes11.05.02.005; 07.05.07.002--Not Available
Adverse reaction08.06.01.0180.000439%Not Available
Anorectal discomfort07.03.03.003--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.001405%
Vulvovaginal pain21.08.02.009--
Neuropsychiatric syndrome19.07.03.009; 17.02.10.0140.000439%Not Available
Application site haemorrhage24.07.01.048; 12.07.01.040; 08.02.01.0400.002458%Not Available
Eye ulcer06.08.03.0180.000439%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000439%
Burning sensation mucosal17.02.06.031; 08.01.06.020--Not Available
Malignant melanoma in situ23.08.01.004; 16.03.01.0040.000658%Not Available
Lip erosion07.05.06.0110.000966%Not Available
Genital erythema23.03.06.019; 21.10.01.0150.000439%Not Available
Subacute cutaneous lupus erythematosus23.03.02.020; 15.06.02.012; 10.04.03.0120.001097%Not Available
Skin plaque23.03.03.0440.003688%Not Available
Chronic papillomatous dermatitis23.01.04.005; 12.02.16.0020.001405%Not Available
Bacterial vulvovaginitis21.14.02.013; 11.02.01.052--Not Available
Chronic cutaneous lupus erythematosus23.03.02.022; 15.06.02.013; 10.04.03.0130.000658%Not Available
Drug effective for unapproved indication12.09.02.001; 08.06.01.0370.000966%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.005707%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.013--Not Available
Therapeutic product effect incomplete08.06.01.0520.001932%Not Available
Therapy non-responder08.06.01.0630.002502%Not Available
Therapy partial responder08.06.01.0640.002502%Not Available
Treatment noncompliance12.09.02.006; 08.06.01.0670.000439%Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene